An update on thyroid disorders in the postpartum period

Abstract

Purpose To review the pathophysiology, diagnosis and management of postpartum thyroid dysfunction, and related management of thyroid disorders during lactation. Methods We reviewed the literature on postpartum thyroid dysfunction and management of thyroid disorders during lactation. ResultsThe postpartum period is characterized by a rebound from the immunotolerance induced by pregnancy. Routine thyroid function screening is not recommended for asymptomatic women in the postpartum period. Testing thyroid function should be considered at 6-12-week postpartum for high-risk populations, including women with a previous episode of postpartum thyroiditis, Graves' disease, or those with Hashimoto's thyroiditis on thyroid hormone replacement, known thyroid peroxidase antibody positivity, type 1 diabetes mellitus, other nonthyroidal autoimmune disease, or chronic hepatitis C. A serum TSH should also be checked in the setting of postpartum depression or difficulty lactating. If patients have thyrotoxicosis, new-onset or recurrent Graves' disease must be differentiated from postpartum thyroiditis, because the management differs. Periodic thyroid function testing is recommended following recovery from postpartum thyroiditis due to high lifetime risk of developing permanent hypothyroidism. Levothyroxine, and the lowest effective dose of antithyroid drugs, (propylthiouracil, methimazole, and carbimazole) can be safely used in lactating women. The use of radiopharmaceutical scanning is avoided during lactation and radioactive iodine treatment is contraindicated. Conclusions Diagnosing postpartum thyroid dysfunction is challenging, because symptoms may be subtle. A team approach involving primary care providers, endocrinologists, and obstetricians is essential for transitioning thyroid care from the gestational to the postpartum setting.

Current concepts regarding Graves’ orbitopathy

“…The postpartum period is a triggering event for Graves' hyperthyroidism [116]. Postpartumassociated rebound immune phenomena may also favor relapse of hyperthyroidism [117,118].…”

Capsiate ameliorates secondary hyperparathyroidism by improving insulin sensitivity and inhibiting angiogenesis

“…The study involved 7 healthy volunteers and 7 patients diagnosed with secondary hyperthyroidism, based on iPTH levels greater than 240 pg/mL and serum calcium levels equal to or greater than 8.4 mg/ dL. All patients met the following inclusion criteria: (1) confirmed diagnosis of chronic renal failure (uremia stage), (2) no improvement in symptoms after 3-6 months of standard medical therapy, and blood PTH levels greater than 1000 ng/L, (3) severe hypercalcemia or hyperphosphatemia, more than one parathyroid hyperplasia lesion on ultrasonography with a diameter greater than 1 cm and (4) normal liver function and blood coagulation parameters. Exclusion criteria included primary hyperparathyroidism, severe illnesses affecting other organs, inability to cooperate during the study and subsequent follow-up.…”

Selenium Supplementation in Pregnant Women with Autoimmune Thyroiditis: A Practical Approach

“…Moreover, euthyroid females with positive TPOAb and/or TgAb may develop postpartum thyroiditis (PPT) [ 85 ], a painless destructive thyroiditis due to the immunity rebound within the first postpartum year [ 85 , 86 ]. Noteworthily, patients with the highest TPOAb titers during pregnancy have the highest PPT risk [ 87 ].…”